- Home
- LXEH vs NCNA Comparison
LXEH vs NCNA Comparison
Compare LXEH & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- NCNA
- Stock Information
- Founded
- LXEH 2001
- NCNA 1997
- Country
- LXEH China
- NCNA United Kingdom
- Employees
- LXEH N/A
- NCNA N/A
- Industry
- LXEH Other Consumer Services
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- NCNA Health Care
- Exchange
- LXEH Nasdaq
- NCNA Nasdaq
- Market Cap
- LXEH 4.7M
- NCNA 4.4M
- IPO Year
- LXEH 2020
- NCNA 2017
- Fundamental
- Price
- LXEH $2.20
- NCNA $1.49
- Analyst Decision
- LXEH
- NCNA Buy
- Analyst Count
- LXEH 0
- NCNA 2
- Target Price
- LXEH N/A
- NCNA $25.00
- AVG Volume (30 Days)
- LXEH 32.0K
- NCNA 138.4K
- Earning Date
- LXEH 09-27-2024
- NCNA 11-26-2024
- Dividend Yield
- LXEH N/A
- NCNA N/A
- EPS Growth
- LXEH N/A
- NCNA N/A
- EPS
- LXEH N/A
- NCNA N/A
- Revenue
- LXEH $5,628,870.00
- NCNA N/A
- Revenue This Year
- LXEH N/A
- NCNA N/A
- Revenue Next Year
- LXEH N/A
- NCNA N/A
- P/E Ratio
- LXEH N/A
- NCNA N/A
- Revenue Growth
- LXEH N/A
- NCNA N/A
- 52 Week Low
- LXEH $2.11
- NCNA $1.49
- 52 Week High
- LXEH $65.06
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- LXEH 37.83
- NCNA 34.09
- Support Level
- LXEH $2.80
- NCNA $1.53
- Resistance Level
- LXEH $2.75
- NCNA $1.66
- Average True Range (ATR)
- LXEH 0.23
- NCNA 0.09
- MACD
- LXEH -0.07
- NCNA 0.05
- Stochastic Oscillator
- LXEH 4.58
- NCNA -3.70
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.